Anika Therapeutics, Inc.
ANIK
$9.76
-$0.12-1.22%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 27.82M | 28.22M | 26.17M | 30.60M | 29.56M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 27.82M | 28.22M | 26.17M | 30.60M | 29.56M |
| Cost of Revenue | 12.23M | 13.86M | 11.49M | 12.87M | 10.15M |
| Gross Profit | 15.58M | 14.36M | 14.68M | 17.73M | 19.41M |
| SG&A Expenses | 11.87M | 12.23M | 12.91M | 11.32M | 13.54M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 31.05M | 32.40M | 30.45M | 30.70M | 29.64M |
| Operating Income | -3.23M | -4.18M | -4.28M | -100.00K | -81.00K |
| Income Before Tax | -2.24M | -3.97M | -3.87M | 38.00K | 325.00K |
| Income Tax Expenses | 939.00K | 681.00K | 89.00K | 2.52M | 2.17M |
| Earnings from Continuing Operations | -3.18M | -4.65M | -3.96M | -2.49M | -1.85M |
| Earnings from Discontinued Operations | 846.00K | 677.00K | -915.00K | -19.38M | -28.07M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.33M | -3.97M | -4.87M | -21.87M | -29.92M |
| EBIT | -3.23M | -4.18M | -4.28M | -100.00K | -81.00K |
| EBITDA | -1.83M | -2.91M | -2.69M | 2.09M | 52.00K |
| EPS Basic | -0.16 | -0.28 | -0.34 | -1.50 | -2.03 |
| Normalized Basic EPS | -0.10 | -0.17 | -0.17 | 0.03 | 0.01 |
| EPS Diluted | -0.16 | -0.28 | -0.34 | -1.50 | -2.03 |
| Normalized Diluted EPS | -0.10 | -0.17 | -0.17 | 0.03 | 0.01 |
| Average Basic Shares Outstanding | 14.42M | 14.36M | 14.30M | 14.58M | 14.77M |
| Average Diluted Shares Outstanding | 14.42M | 14.52M | 14.30M | 14.62M | 14.77M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |